Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 4/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496267 | 1.00 | POLB (0.47) | POLBMEN1KMT2ALMNAGPR119 | |
| SCHEMBL25874513 | 0.88 | LMNA (0.47) | POLBMEN1KMT2ALMNAGPR119 | |
| SCHEMBL25297742 | 0.82 | ALDH1A1 (0.40) | MEN1KMT2ALMNAMAPT | |
| SCHEMBL19869973 | 0.81 | LMNA (0.51) | POLBMEN1KMT2ALMNAGPR119 | |
| SCHEMBL25738732 | 0.81 | POLB (0.49) | POLBMEN1KMT2ALMNAGPR119 | |
| SCHEMBL30478271 | 0.81 | POLB (0.49) | POLBMEN1KMT2ALMNAGPR119 | |
| SCHEMBL25238790 | 0.76 | EHMT2 (0.48) | POLBMEN1KMT2ALMNAMAPT | |
| SCHEMBL10248751 | 0.75 | MEN1 (0.54) | POLBMEN1KMT2AGPR119MAPT | |
| SCHEMBL19869962 | 0.75 | LMNA (0.46) | POLBMEN1KMT2ALMNASTS | |
| SCHEMBL25738979 | 0.73 | POLB (0.65) | POLBMEN1KMT2ALMNAGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452984-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Molecure S.A. (PL) | 2024-10-30 | — | — | EP | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| WO-2023119233-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023119233-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | POLB 2336/4885MEN1 2177/4885KMT2A 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.